urea has been researched along with Triple Negative Breast Neoplasms in 6 studies
pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.
Triple Negative Breast Neoplasms: Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Compared to free GA, the optimized PEUU nanocarrier improves the intratumoral distribution of GA by more than 9-fold, which significantly enhances the bioavailability and persistence of GA after intravenous administration." | 1.91 | Optimization of amino acid-based poly(ester urea urethane) nanoparticles for the systemic delivery of gambogic acid for treating triple negative breast cancer. ( Bian, Z; Chu, CC; Ji, Y; Kwan, HY; Li, J; Xiao, S, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Ji, Y | 1 |
| Li, J | 1 |
| Xiao, S | 1 |
| Kwan, HY | 1 |
| Bian, Z | 1 |
| Chu, CC | 1 |
| Ashraf-Uz-Zaman, M | 1 |
| Shahi, S | 1 |
| Akwii, R | 1 |
| Sajib, MS | 1 |
| Farshbaf, MJ | 1 |
| Kallem, RR | 1 |
| Putnam, W | 1 |
| Wang, W | 1 |
| Zhang, R | 1 |
| Alvina, K | 1 |
| Trippier, PC | 1 |
| Mikelis, CM | 1 |
| German, NA | 1 |
| Vande Voorde, J | 1 |
| Ackermann, T | 1 |
| Pfetzer, N | 1 |
| Sumpton, D | 1 |
| Mackay, G | 1 |
| Kalna, G | 1 |
| Nixon, C | 1 |
| Blyth, K | 1 |
| Gottlieb, E | 1 |
| Tardito, S | 1 |
| Shin, S | 1 |
| Wolgamott, L | 1 |
| Tcherkezian, J | 1 |
| Vallabhapurapu, S | 1 |
| Yu, Y | 1 |
| Roux, PP | 1 |
| Yoon, SO | 1 |
| Bryant, C | 1 |
| Rawlinson, R | 1 |
| Massey, AJ | 1 |
| Min, DJ | 1 |
| He, S | 1 |
| Green, JE | 1 |
6 other studies available for urea and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
Optimization of amino acid-based poly(ester urea urethane) nanoparticles for the systemic delivery of gambogic acid for treating triple negative breast cancer.
Topics: Amino Acids; Animals; Esters; Humans; Mice; Nanoparticles; Triple Negative Breast Neoplasms; Urea; U | 2023 |
Design, synthesis and structure-activity relationship study of novel urea compounds as FGFR1 inhibitors to treat metastatic triple-negative breast cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Design; Female; Humans; Mice, Inbr | 2021 |
Improving the metabolic fidelity of cancer models with a physiological cell culture medium.
Topics: Arginine; Argininosuccinate Lyase; Cell Line, Tumor; Cell Proliferation; Culture Media; Female; Ferr | 2019 |
Glycogen synthase kinase-3β positively regulates protein synthesis and cell proliferation through the regulation of translation initiation factor 4E-binding protein 1.
Topics: Adaptor Proteins, Signal Transducing; Animals; Cell Cycle Proteins; Cell Growth Processes; Enzyme In | 2014 |
Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers.
Topics: Benzodiazepinones; Biomarkers, Tumor; Cell Line, Tumor; Checkpoint Kinase 1; Cisplatin; Deoxycytidin | 2014 |
Birinapant (TL32711) Improves Responses to GEM/AZD7762 Combination Therapy in Triple-negative Breast Cancer Cell Lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Checkpoint Kinase 1; De | 2016 |